Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Aug 23, 2013

NEW YORK (GenomeWeb News) – Circulating tumor cell diagnostics developer Epic Sciences has appointed Murali Prahalad to be president and CEO.

Prahalad formerly held multiple posts at Life Technologies, and most recently he was VP of corporate strategies. In that role, he helped shape investment priorities across Life Tech’s research tools, clinical diagnostics, and applied markets portfolios, said Epic in a statement.

Before he joined Life Technologies, he was VP of business development at Sequenom, and he was a consultant for The Advisory Board Company and an analyst at Gemini Consulting in Tokyo.

Bruker has appointed Thomas Bachmann to be president of its Bruker BioSpin Group. He will be responsible for two divisions: the Magnetic Resonance Spectroscopy division, which includes NMR, electron paramagnetic resonance, and compact magnetic resonance, and the Preclinical Imaging division, which includes MRI, magnetic particle imaging, X-ray micro-CT, and optical and PET/SPECT/CT molecular imaging.

Bachmann was CEO of Tecan for seven years, and for two years before that he was CEO of the Arbonia-Forster Group’s Steel Systems business.

The National Cancer Institute said this week that it has appointed Stephen Chanock to be director of NCI’s Division of Cancer Epidemiology and Genetics and a scientific director of the institute.

Chanock takes over DCEG from founding Director Joseph Fraumeni, who stepped down from the post a year ago.

Chanock formerly was a tenured investigator in the Genomic Variation Section of the Pediatric Oncology Branch in NCI’s Center for Cancer Research, he was co-chair of NCI’s Genetics, Genomics, and Proteomics Faculty, and he was chief of the Cancer Genomics Research Laboratory and the Laboratory of Translational Genomics. He also was acting director of the NCI Center for Cancer Genomics from 2012 to 2013.

MBio Diagnostics has appointed Robert Silverman to serve on its board of directors.

Silverman has been CEO of the in vitro diagnostics company mtm Laboratories, where he developed a portfolio of tools for diagnosing and detecting cervical cancer. He also negotiated the purchase of mtm by Roche Diagnostics and helped integrate the company into Roche.

Silverman also previously was senior VP of worldwide commercial operations at ViaCell, and he spent six years with Cytyc, where he was VP of marketing and helped launched the firm’s cervical cancer screening test.

He also was director of new product development for Abbott Laboratories' Pharmaceutical Products Division, and a management consultant with Bain and Company.

DNAnexus has appointed Arthur Cole to be its general manager, Europe.

Cole previously was a managing partner at the consulting firm Debon Strategic Partners, where he provided strategic analysis, business planning, and interim management services to biotech and molecular diagnostics companies, and he was VP at Visible Genetics, which was acquired by Bayer Diagnostics.

He also held senior leadership posts over a 13-year period with Pharmacia Biotech, including managing the company’s global commercial operations and leading strategic planning.

Provista Diagnostics said this week that Joseph Eggler has joined the company as chief commercial officer. In the job, he will execute and manage the company’s sales efforts, as well as commercial aspects of the business.

Eggler previously was at Prometheus Laboratories, where he spent 12 years, and he has over two decades of experience in planning, sales and marketing development, and in identifying and creating key relationships, Provista said.

The International Society for Computational Biology has appointed Alfonso Valencia and Thomas Lengauer as president-elect and vice president, respectively.

Valencia is the group leader of the structural computational biology group at the Spanish National Cancer Research Center. He is an ISCB Fellow and has been involved with the leadership of the organization since its international expansion in 2002. He currently serves on its board of directors and chairs several of its committees. He will begin serving as president-elect in January 2014 and will begin a three-year term as president in 2015.

Lengauer is the director of the computational biology and applied algorithms group at the Max Planck Institute for Informatics. He has been involved with ISCB since the late 1990s and is a member of its board of directors. He will serve as vice president starting January 2014 for a three-year term.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.